ArticleBMC global and public health2025
Tracing leprosy trends in Pakistan: a two-decade analysis of geographic and demographic shifts (2001-2023).
Article in BMC global and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Delayed diagnosis as a barrier to Zero Leprosy: Lived experiences from Pakistan.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeprosy, or Hansen's disease, is caused by Mycobacterium leprae and can lead to severe disabilities, social marginalisation and reduced quality of life. The disease remains a public health challenge in many low- and middle-income countries, including Pakistan. This study aimed to examine trends in leprosy cases diagnosed in Pakistan from 2001 to 2023, focusing on key epidemiological indicators such as sex, leprosy subtype, age, child cases, disability proportion and geographic distribution to reveal insights into the current situation and to inform strategies for improving case detection.
methodsThis retrospective study analysed data from the Marie Adelaide Leprosy Centre (MALC), which operates 205 treatment centres across Pakistan. Leprosy cases diagnosed between 2001 and 2023 were examined for sociodemographic and clinical characteristics, including sex, age, and leprosy subtype. Descriptive statistics were presented for leprosy cases diagnosed during this period, and maps were created to illustrate geographic trends and distributions in leprosy incidence over four 5-year intervals between 2003 and 2022.
resultsA total of 10,573 new leprosy cases were recorded with a median age of 36 years. Most cases (79.3%) were multibacillary (MB) leprosy. Until 2013, the majority of patients were male, but the proportion of female cases has steadily increased since then, rising from 40.4% in 2021 to 50.0% in 2023. The highest incidence was observed in Karachi, Sindh, and northern regions, including Khyber Pakhtunkhwa and Gilgit-Baltistan. The overall incidence of new cases declined steadily from 971 in 2001 to 236 in 2023. A decline in child cases and grade 2 disability proportions was also observed. Over the study period, 852 cases (8.1%) occurred in children under 15 years of age, while in 2023 specifically, 7.6% of new cases were in children and 17.4% presented with grade 2 disability, both key indicators for monitoring leprosy epidemiology. However, a substantial increase in the MB proportion was observed in 2023.
conclusionsThese findings indicate significant progress in leprosy control in Pakistan, but also highlight persistent transmission in specific regions. Targeted interventions in high-burden areas, along with sustained community-based case-finding and early diagnosis efforts, are essential for continued progress toward leprosy elimination in Pakistan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.